Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?

Acta Psychiatrica Scandinavica

Volumn 127, Issue 6, 2013, Pages 474-481

  Schennach, R ^a   Riesbeck, M ^b   Mayr, A ^a,c   Seemuller F ^a   Maier, W ^d   Klingberg, S ^e   Heuser, I ^f   Klosterkotter J ^g   Gastpar, M ^h   Schmitt, A ^b,i   Sauer, H ^j   Schneider, F ^k   Jager M ^a   Wolwer W ^b   Gaebel, W ^b   Moller H J ^a   Riedel, M ^a,l  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h Rhein Hospital Essen   (Germany)

ⁱ CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^j FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^k RWTH AACHEN UNIVERSITY   (Germany)

^l Vinzenz von Paul Hospital   (Germany)

more..

Author keywords

Early response; First episode schizophrenia; Long term study; Predictive validity

Indexed keywords

BIPERIDEN; HALOPERIDOL; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; DISEASE DURATION; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; YOUDEN INDEX;

ADULT; ANTIPSYCHOTIC AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; LONGITUDINAL STUDIES; MALE; RISPERIDONE; ROC CURVE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877716024     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12006     Document Type: Article

References (28)

1. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005;57:12.
2. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60:1228-1235.
3. Correll CU, Malhotra AK, Kaushik S, Mcmeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063-2065.
4. Chang YC, Lane HY, Yang KH, Huang CL. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006;26:554-559.
5. Lambert M, Naber D, Schacht A et al. Rates and predictors of remission and recovery during 3years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 2008;118:220-229.
6. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007;89:129-139.
7. Kinon BJ, Chen L, Ascher-Svanum H et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010;35:581-590.
8. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry 2007;68:1522-1527.
9. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-191.
10. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006;163:743-745.
11. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998;172:53-59.
12. Nielsen J, Le QP, Emborg C, Foldager L, Correll CU. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010;122:356-366.
13. Simonsen E, Friis S, Opjordsmoen S et al. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand 2010;122:375-383.
14. Gaebel W, Riesbeck M, Wolwer W et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007;68:1763-1774.
15. Moller HJ, Riedel M, Jager M et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008;11:985-997.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Association, 1994.
17. Cording C. Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr Prax 1998;25:175-178.
18. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.
19. Leucht S, Engel R. Developing clinically meaningful criteria of "response" that can be used as standards in systematic reviews by equipercentile linking. Cochrane Colloquium Abstracts 2008:17-167.
20. Weinstein MC, Fineberg HV. Clinical decisions analysis. Philadelphia, PA: WB Saunders, 1980.
21. R Development Core Team. A language and environment for statistical computing. Vienna, Austria: Foundation for Statistical Computing, http://www.R-project.org. 2008.
22. Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6weeks of nonresponse?J Clin Psychopharmacol 2010;30:176-180.
23. Jager M, Schmauss M, Laux G et al. Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study. Eur Psychiatry 2009;24:501-506.
24. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?Schizophr Res 2005;79:231-238.
25. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325.
26. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007;32:1903-1910.
27. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 2008;50:419-430.
28. Rabinowitz J, Bromet EJ, Davidson M. Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?Schizophr Res 2003;61:149-155.